OLY Stock Chart & Stats
€11.00
-€0.05(-0.54%)
At close: 4:00 PM EDT
€11.00
-€0.05(-0.54%)
Day’s Range― - ―
52-Week Range€6.80 - €11.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.76B
Enterprise Value€12.29B
Total Cash (Recent Filing)€151.18B
Total Debt (Recent Filing)€316.79B
Price to Earnings (P/E)24.2
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)69.94
Shares Outstanding1,114,485,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)2.08
Price to Sales (P/S)1.67
P/FCF Ratio93.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)€6.10B
Bulls Say, Bears Say
Bulls Say
Strong Operating MarginsHigh gross and EBITDA margins indicate meaningful operating scale and a profitable medical-device model. If maintained, this margin structure can support investment in innovation, customer support, and installed-base expansion while providing resilience against moderate cost pressure.
Manageable LeverageManageable leverage and a substantial equity base give Olympus financial flexibility to support product development, capital investment, and customer solutions. Lower balance-sheet strain also improves its ability to withstand procedure or hospital-spending fluctuations over the next several quarters.
Improved Free Cash FlowThe sharp TTM improvement in free cash flow strengthens internally generated funding for research, commercial investment, and shareholder or debt obligations. Better cash conversion than the latest annual period supports near-term financial flexibility, even though consistency remains important.
Bears Say
Modest Revenue GrowthModest revenue expansion suggests Olympus is not currently converting its medical-technology position into rapid top-line growth. Slower growth can limit operating leverage and make future margin progress more dependent on efficiency, product mix, or procedure-volume improvement.
Declining Earnings MomentumThe sharp negative EPS growth signal points to weaker earnings momentum than the company’s gross and EBITDA margins imply. Persistently uneven bottom-line performance could constrain reinvestment capacity and make operating results less predictable across the next two to six months.
Choppy Cash ConversionHistorical periods of negative or weak free cash flow show that accounting profitability has not consistently translated into cash generation. Such volatility can complicate funding plans and reduce confidence that reported earnings will steadily support investments and obligations.
Olympus News
OLY FAQ
What was Olympus’s price range in the past 12 months?
Olympus lowest stock price was €6.80 and its highest was €11.30 in the past 12 months.
What is Olympus’s market cap?
Olympus’s market cap is €10.76B.
When is Olympus’s upcoming earnings report date?
Olympus’s upcoming earnings report date is Nov 10, 2026 which is in 15 days.
How were Olympus’s earnings last quarter?
Olympus released its earnings results on Aug 07, 2026. The company reported €0.1 earnings per share for the quarter, beating the consensus estimate of €0.048 by €0.052.
Is Olympus overvalued?
According to Wall Street analysts Olympus’s price is currently Overvalued.
Does Olympus pay dividends?
Olympus does not currently pay dividends.
What is Olympus’s EPS estimate?
Olympus’s EPS estimate is 0.13.
How many shares outstanding does Olympus have?
Olympus has 1,114,485,700 shares outstanding.
What happened to Olympus’s price movement after its last earnings report?
Olympus reported an EPS of €0.1 in its last earnings report, beating expectations of €0.048. Following the earnings report the stock price went up 4.124%.
Which hedge fund is a major shareholder of Olympus?
Currently, no hedge funds are holding shares in DE:OLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olympus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.48%
12-Months-Change
Fundamentals
Return on Equity
10.21%
Trailing 12-Months
Asset Growth
-5.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Olympus
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The company structures its operations around three primary divisions: Endoscopic Solutions, Therapeutic Solutions, and Other business segments. Its extensive product portfolio includes advanced gastrointestinal endoscopy systems, incorporating video and ultrasound technologies, as well as GI endotherapy tools for treating colorectal conditions, HPB (hepatopancreatobiliary) issues, and hemostasis. Olympus also delivers comprehensive endoscopic ecosystem solutions, which feature intelligent operating software platforms, AI-driven insights, and computer-aided detection and diagnosis functionalities. Furthermore, it provides reprocessing solutions for endoscopes, including reprocessors, chemicals, and related accessories, supported by essential medical services such as repair center operations. The company also supplies respiratory care devices, offering bronchoscopy systems and solutions for lung cancer and chronic obstructive pulmonary disease. Its urology offerings encompass visualization tools, stone management, and treatments for benign prostatic hyperplasia (BPH) and BPH with bladder cancer. Within its surgical segment, Olympus features surgical endoscopy systems, cutting-edge energy devices, surgical microscopes, integrated operating room solutions, rhino-laryngoscopy systems, and instruments tailored for ear, nose, and throat surgeries. Various gastroenterology and gynecology devices further round out its product offerings. Established in 1919, the company was initially known as Olympus Optical Co., Ltd., before officially changing its name to Olympus Corporation in October 2003. Its global headquarters are situated in Hachioji, Japan.
OLY Company Deck
OLY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant near-term operational and regulatory challenges (FDA observations, product ship holds, one-off gross margin/COGS impacts, and increased restructuring provisioning) against clear signs of stabilization and management actions (China recovery, majority of products released, leadership changes, disciplined commercial remediation and maintained mid-term targets). Management emphasized these are addressable, one-off or execution-related issues and reiterated long-term margin and growth ambitions, but material short-term impacts keep the tone cautious.View all DE:OLY earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Koninklijke Philips
―
Medtronic
―
Smith & Nephew Snats
―
Stryker
―
GE Healthcare Technologies Inc
―









